How to calculate the base dose

The use of BED models in radiotherapy treatment planning systems allows for voxel-level optimization, addressing the challenge of comparing and combining biological effects across different radiation therapies, thereby optimizing treatment plans for enhanced tumor control and reduced complications.

JP2024544973APending Publication Date: 2024-12-05MIM SOFTWARE INC +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024527848
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-11
Filing Date
2022-11-11
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Existing radiotherapy treatment modalities lack a standardized method to accurately compare and combine biological effects across different radiation therapies due to variations in particle type, dose rate, and fractionation schedule, leading to inadequate assessment of tumor control and normal tissue complications.

Method used

A system and method utilizing biologically effective dose (BED) models to determine a base dose for treatment planning systems (TPS), considering prior treatment information and future therapy plans, enabling voxel-level optimization to achieve desired biological outcomes.

Benefits of technology

Enables accurate comparison and combination of biological effects across different radiotherapy treatments, optimizing treatment plans to minimize complications and enhance tumor control by considering BED distributions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544973000001_ABST
    Figure 2024544973000001_ABST
Patent Text Reader

Abstract

Base dose calculation tool to determine the base dose used in treatment planning. Base treatment information is taken into account on a voxelized and time basis so that subsequent treatments can be planned. Base dose output can be manipulated in existing treatment planning systems.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims the benefit of and priority to U.S. Provisional Patent Application No. 63 / 263,909, filed November 11, 2021, the entire disclosure of which is incorporated herein by reference. [Background technology]

[0002] The biological outcome of a specific dose of radiation varies based on the specifications of particle type, three-dimensional dose distribution, dose rate, fractionation schedule, etc. Therefore, the physical dose alone does not provide an accurate way to compare the expected biological effect between two or more radiation therapy courses that differ by the delivery modality, fractionation schedule, and particle energy and / or type. Examples of radiation therapy modalities where direct physical dose comparison is inappropriate to consider biological effect include conventional and hypofractionated external beam radiation therapy (EBRT), proton therapy, high dose rate (HDR) brachytherapy, and low dose rate (LDR) brachytherapy (BT). Furthermore, a simple summation of the physical dose distributions from different treatment courses is not a useful indicator of expected tumor control or normal tissue morbidity.

[0003] The biologically effective dose (BED) was introduced to quantitatively model the biological effects of radiation therapy. The concept of BED has evolved to take into account several factors, such as dose rate and time between fractions to account for the repair of sublethal damage and cell repopulation during treatment. BED distributions from different forms of radiation therapy can be directly compared or summed to properly assess the biological outcome expected from combinations of radiation therapy. Summary of the Invention [Means for solving the problem]

[0004] A simplified summary is provided herein to enable a basic or general understanding of various aspects of the exemplary and non-limiting embodiments that follow the more detailed description and accompanying drawings. This summary is not intended, however, as an extensive or exhaustive overview. Rather, the sole purpose of this summary is to present some concepts related to some exemplary and non-limiting embodiments in a simplified form as a prelude to the more detailed description of the various embodiments that follow.

[0005] In various non-limiting embodiments, a system and associated method are provided for determining a base dose to be input into a treatment planning system (TPS). Prior treatment information associated with a history of radiation treatments administered to a patient is obtained. Additionally, planned treatment information associated with additional radiation therapy to be administered to the patient is obtained. A base dose is determined based on the prior treatment information and the future planned treatment information. The base dose is determined according to a base dose relationship derived from a biologically effective dose (BED) model associated with the planned therapy. The base dose is exported to the TPS for planning future radiation therapy.

[0006] These and other embodiments are described in more detail below.

[0007] Various non-limiting embodiments are further described with reference to the accompanying drawings. [Brief description of the drawings]

[0008] [Figure 1] FIG. 1 is a diagram illustrating a desired external beam therapy dose per voxel for an exemplary therapy according to one or more embodiments. [Diagram 2] FIG. 2 is a diagram illustrating the concept of base dose optimization to achieve a desired dose distribution in accordance with various embodiments. [Diagram 3] FIG. 3 is a schematic block diagram of an exemplary and non-limiting embodiment for base dose determination in accordance with one or more aspects. [Figure 4]FIG. 4 is a schematic block diagram of an exemplary and non-limiting embodiment for base dose determination in accordance with one or more aspects. [Diagram 5] FIG. 5 illustrates an exemplary, non-limiting embodiment of a method for determining a base dose in accordance with various aspects. [Figure 6] FIG. 6 is a schematic block diagram of an example system for determining a base dose in accordance with one or more embodiments. [Figure 7] FIG. 7 is a schematic block diagram of an exemplary system for determining a base dose in accordance with various embodiments. [Figure 8] FIG. 8 is a schematic block diagram of an example system for determining a base dose in accordance with one or more embodiments. [Figure 9] FIG. 9 is a schematic block diagram of an exemplary and non-limiting embodiment of a computing device associated with the systems of FIGS. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] As mentioned in the background, the biologically effective dose (BED), which is distinct from the physical dose, can be utilized to evaluate and / or compare the biological outcomes of various radiation therapies and / or various radiation therapy combinations. The conversion from physical dose to BED may be based on a linear-quadratic (LQ) model that describes the cell viability after receiving various amounts of radiation from various particle types delivered at various dose rates and / or fractionation schedules. The LQ model is the result of fitting the viability of irradiated cells to a second order polynomial with coefficients α and β as a function of the physical dose. Specifically, the LQ model describes the viability (S) of cells irradiated with a dose (D) over a period of time (T), as generally shown in Equation 1:

[0010]

number

[0011] In Equation 1, E represents the biological effect of radiation exposure on a cell population causing inactivation taking into account the cell number. E can be defined according to Equation 2:

[0012]

number

[0013] In Equation 2, α and β are coefficients that represent the radiosensitivity of tissues, G is a coefficient that represents the dose rate and the repair of sublethal damage (such as the prolonged exposure dose coefficient), and T P is the tumor doubling time, and T K represents the kick-off period until cell regrowth begins after the start of radiation therapy. The α and β values ​​are tissue-specific and represent radiation sensitivity (e.g., sensitivity to fractionation). In an exemplary application, the LQ model accurately represents fractionation effects at doses of 1-10 Gy per fraction.

[0014] BED may be related to Equation 1 and Equation 2, for example according to Equation 3.

[0015]

number

[0016] (BED with fractionated external beam radiation therapy)

[0017] Total dose from external beam radiation therapy (EBRT) (D EBRT ) is G=1 / n EBRT The sublethal damage repair coefficient is expressed as EBRT EBRT may be administered during a “kick-off” period, T K is longer than the total treatment period T, the effect of tumor cell regrowth can be neglected. Substituting these values ​​into Equation 3 results in the following BED model, which is widely used in EBRT:

[0018]

number

[0019] (Derivation of BED-informed EBRT planning method using basic plan)

[0020] In this method, a desired reference BED distribution (BED ref ) and the distribution of previously irradiated BED (BED prior ) are assumed. ref The value can be calculated by converting the accepted physical dose constraints (such as tumor prescription values ​​and organ risk tolerances) corresponding to a specified fractionation scheme using the appropriate BED model. For an irradiated target volume (e.g., a tumor), the BED ref The distribution is the BED at each point. prior and BED EBRT For organs at risk (OARs), BED ref BED prior and BED EBRT and represents the desired maximum BED volume statistic.

[0021] Assuming that the past physical dose distribution is known and a model exists to convert the physical dose from the previous treatment to the BED, the BED is calculated for each voxel. prior It is mathematically straightforward to calculate the remaining BED (BED EBRT ) is simply BED ref and BED prior This is the difference between...

[0022]

number

[0023] However, the EBRT TPS platform optimizes treatment plans using physical dose instead of BED. EBRT is the physical dose (D EBRT ) which must be converted to BED EBRT , number of divisions (n EBRT), and the α / β ratio (α / β), in terms of EBRT dose (D EBRT This is done by solving equation 4:

[0024]

number

[0025] BED EBRT BED ref and BED prior Substituting this into (Equation 5), we get the following:

[0026]

number

[0027] Performing this calculation for each voxel gives n voxels in the target area that need to be irradiated. EBRT A distribution is obtained that represents the total physical dose from the EBRT plan, consisting of the fractionation and the maximum dose to be delivered to the voxels of the organs at risk. A schematic of this process is shown in Figure 1. Figure 1 shows the voxel-wise D EBRT Each dark green box represents the remaining physical dose required for each voxel from EBRT to obtain the desired composite BED.

[0028] Further logistical challenges remain to obtain the EBRT dose distributions described above. Commercially available TPS inverse optimization tools, as shown in Figure 1, do not allow the user to specify the desired physical dose for each voxel, but instead require the user to specify a dose optimization objective (i.e., maximum dose, minimum dose, uniform dose, etc.) that applies to all voxels within the target volume. To address this issue, the base dose (D base A method has been proposed to calculate D base is the BED calculated for the number of fractions of future EBRT treatments. ref The physical dose (Dref ) and D EBRT is equal to the difference between

[0029]

number

[0030] D ref is the structure-specific value for each target or OAR volume, and n EBRT BED when irradiated in fractions ref For target structures, this represents the desired minimum physical dose value of BED corresponding to the BED of the reference prescribed tumor dose, and for OARs, this is the maximum physical dose value of BED corresponding to the BED of the maximum dose constraint commonly used in conventional RT. D ref The formula is that the BED term is BED ref It is derived in the same way as Equation 6, except that it is given by

[0031]

number

[0032] Substituting Equations 6 and 9 into Equation 8 and simplifying the terms, we obtain the following D base The following formula is obtained.

[0033]

number

[0034] This calculation, voxel by voxel, results in a base dose distribution that is intended to be imported into the EBRT TPS. In some exemplary embodiments herein, inverse optimization is employed to generate the EBRT plan. Modern TPS platforms allow the generation of an EBRT plan by specifying a "base dose" or a "bias dose," so that the sum of the base dose and the new EBRT plan attempts to achieve the input optimization goal. This technique is similar to the IMRT plan (D EBRT,actual ) and Dbase The sum of and for voxels within the target volume is D ref and for all non-target voxels D ref It is used to account for radiation dose from prior treatment by optimizing the EBRT plan so that the radiation dose is less than

[0035] In embodiments where the TPS supports per-voxel dose targets rather than per-contour dose targets, or where contours are currently defined per-voxel, EBRT can also be imported directly into the TPS to define the desired dose components per voxel in the EBRT course, or the optimizer can calculate Eq. 8 in the objective function to EBRT Optimize to D ref In achieving this, the already irradiated D base It is possible to incorporate.

[0036] (Example Planning Procedure)

[0037] An exemplary planning procedure based on the above concepts involves the use of prior treatment planning CT and / or MRI of the target and organs at risk (OAR) structures and previously delivered dose distributions (D prior ) and import it into your TPS program.

[0038] A secondary EBRT radiotherapy simulation CT is performed and imported into the TPS program.

[0039] The previous images can then be registered to the second radiation treatment simulation image using tools provided by the TPS. If acceptable anatomical fusion is not possible due to tissue / cavity deformation, deformable image registration may be used. The dose from the previous treatment is mapped onto the second EBRT simulation CT using image registration. When using the deformable registration tool, the deformation registration information is used to calculate the D priorThe distribution may be deformably mapped, and quadratic RT plan contours are generated. Next, the BED of each RT plan contour is calculated. ref and associated tissue-specific BED parameters (i.e., , , etc.) are specified. The tissue-specific BED parameters are calculated by BED-ing the physical dose of the preceding treatment mapped onto the EBRT simulation CT using the appropriate BED model. prior Finally, for each voxel on the EBRT simulation CT, D is calculated using Eq. base is calculated. Figure 3 shows the conversion process.

[0040] Then, the secondary EBRT simulation CT, secondary RT planning contour, and D base The distribution is imported into the secondary EBRT treatment planning system. In this step, the relevant DICOM header information (e.g. patient demographics) of the base TPS can be edited to ensure that the information matches the data in the secondary TPS to avoid import incompatibility issues. The RT plan (D EBRT,actual ) is generated. D base and D EBRT,actual The composite dose distribution consisting of the sum of is evaluated and, if necessary, reoptimized until an acceptable secondary RT plan is produced.

[0041] In another embodiment, the base RT physical dose is base The conversion from the base RT physical dose to D can be calculated using a separate third dose conversion system. base The transformation to may be calculated using the quadratic RT TPS.

[0042] (Improvement of base dose determination method)

[0043] In clinical practice, when a patient receives external beam radiation therapy after previous radiation therapy (e.g., radioembolization, molecular beam therapy, brachytherapy, proton therapy, etc.) or other techniques that may affect cell viability, the expected biological effects must be considered to define the prescribed dose that optimizes the treatment outcome. One traditional approach to this is either (I) non-voxelized estimation using models based on values ​​summarized from the dose distribution, or (II) biological treatment planning plug-ins. Biological treatment planning plug-ins are expensive, have not been widely adopted, and do not consider building one treatment on top of another with different biological dosimetric effects.

[0044] This document describes a general and improved technique for determining base doses to be used in treatment planning, which allows future treatments to be planned taking into account prior treatment doses on a voxelized basis, and the base dose output can be manipulated by conventional treatment planning systems and is not computationally intensive.

[0045] As mentioned above, the biologically effective dose (BED) is a more useful measure of the expected biological effect of radiation therapy or other therapies. The physical dose is a less useful indicator of biological effect, especially when considering expected tumor control and normal tissue morbidity. When considering situations involving multiple treatments and / or treatment with multiple different modalities, additivity is desirable in order to develop treatment plans that reduce complications.

[0046] In general, a treatment plan can satisfy two conditions. The first condition is a biological condition, which specifies that the biologically effective dose (BED) of the preceding treatment, in addition to the biologically effective dose (BED) of the planned treatment, should achieve a reference BED or a threshold BED. The second condition is a physical condition, which specifies that the physical dose planned for the future treatment, in addition to the past physical dose or base dose, should achieve a reference dose (e.g., a dose constraint). It should be understood that these conditions can be evaluated point by point. In practice, since the treatment plan is based on medical images, these conditions can be considered voxel by voxel.

[0047] As mentioned above, conventional treatment planning system (TPS) platforms typically optimize treatment plans based on the physical dose. Optimizing based on the physical dose (i.e., satisfying the second (physical) condition) may lead to violation of the first (biological) condition in conventional approaches. BED is a nonlinear phenomenon. Considering the physical dose alone cannot account for all biological constraints. Similarly, BED is not a direct surrogate for the physical dose due to its nonlinearity.

[0048] The technique for determining the base dose is described below. The determined base dose value can be input to a conventional TPS platform that optimizes according to the physical dose. The base dose is determined such that the TPS platform takes into account the biological constraints defined using the BED when optimizing for the physical dose. The base dose does not have a direct physical meaning, but serves as a proxy that allows the TPS platform to optimize to meet the reference BED. The base dose is distinct from the actual physical dose of the preceding treatment, but is a value that represents, corresponds to, and is derived from the BED of the preceding treatment.

[0049] According to one aspect, the base dose is determined based on the relationship that occurs between BED and dose (e.g., fractionated dose). According to one embodiment, Equation 4 above can be utilized to define this relationship. For example, a quadratic equation created by distributing D can be solved to generate the relationship between D and BED. Further, in this embodiment, this value D, defined according to BED, can be used in the model described above. For example, the equation for D can be utilized in place of the equivalent dose (EQD), and then the base dose D base can be determined.

[0050] In accordance with various aspects, a base dose determination tool is provided that takes as input the biologically effective dose (BED) of any treatment and outputs a base dose that can be imported into a treatment planning system to achieve a plan that satisfies the BED constraints. In some embodiments, the tool utilizes a relationship based on the Linear-Quadratic (LQ) BED model as described above.

[0051] In one embodiment, as generally shown in FIG. 4, the tool receives as input, for example, contours, user-defined parameters (e.g., radiobiological parameters, etc.), optimization parameters (e.g., dose constraints, and prior treatment BED map registered to a series (e.g., simulation images) used for treatment planning). The tool matches the contours of the simulation images with ranked tissue-specific user-defined and optimization parameters. The tool can create parameter maps and reference doses by substituting the user-defined and optimization parameters from the ideal plan into the contours according to rank. The tool may then apply base dose relationships on a voxel-by-voxel basis on the parameter maps, reference doses, and prior treatment BED maps. As output, the tool provides the base dose.

[0052] In various embodiments, contour matching defines how parameter maps and reference doses are generated, which are necessary arguments to the base dose relation and are used to determine the desired voxelization output using a lightweight method.

[0053] In one embodiment, the additional treatment may be for a cancer suspected of recurrence that would then require additional treatment in the future. In this embodiment, the "up-front dose" may be a simulated dose predicted in the future based on a statistical model of the predicted location of recurrence and time to recurrence and the required future treatment dose. In this embodiment, the result of the planned treatment optimization is a treatment plan with a sufficiently dose-sparing OAR to allow for the safe delivery of future treatment.

[0054] FIG. 5 is a flow diagram of an exemplary and non-limiting base dose determination method 100 utilized in treatment planning for additional treatment. In one embodiment, the method 100 is suitable for planning radiation therapy following a prior treatment. The additional treatment may or may not be different from the prior treatment. For example, as in the above example, the prior treatment may be LDR BT and the additional treatment may be EBRT. However, it should be understood that the techniques described herein are not limited to these therapies and may be employed in combination with other therapies, including one or more of BT, EBRT, radioembolization therapy, molecular beam therapy, proton beam therapy, and the like.

[0055] The method 100 may begin at step 102, where a set of inputs is obtained. The set of inputs may include, for example, contours, radiobiological parameters for additional treatments, and optimization parameters (e.g., dose constraints). The contours may indicate regions of interest, such as, but not limited to, OARs and target volumes. The optimization parameters may be set for each contour and indicate respective reference doses for the corresponding regions. The radiobiological parameters may be defined for each contour or may be specific to the treatment. For example, for EBRT, the biological modeling parameters may include n (e.g., number of fractions) and α / β (e.g., indicating tissue-specific radiosensitivity).

[0056] In step 104, a parameter map and a reference dose are generated based on a set of inputs. The parameter map and the reference dose can be generated by matching the contours to the radiobiological parameters and the optimization parameters. Once matched, the parameters and the optimization parameters can be substituted into the contours to generate the map and the reference dose.

[0057] In step 106, a biologically effective dose (BED) map of the prior treatment is obtained. The prior treatment is sometimes referred to herein as a base treatment. In some embodiments, the prior BED map is registered to a simulation image (e.g., a series used for treatment planning). The prior BED map provides the BED of the region of interest from the prior treatment.

[0058] In step 108, a base dose is determined based on the parameter map, the reference dose, and the BED map from the previous treatment. For example, the parameter map and the reference dose can provide a BED map for a boost treatment. Using the above relationship, the BED map from the previous treatment and the parameter map / reference dose are input into the relationship to calculate a base dose appropriate for the treatment plan. In step 110, the base dose is exported to a treatment planning system.

[0059] Please refer to FIG. 6. FIG. 6 is a schematic block diagram of an exemplary and non-limiting embodiment of a base dose calculation system 200. As shown, the system 200 can include a computing device 210 that implements a base dose calculation tool 300. The computing device 210 may include a processor and various computer-readable storage media (e.g., volatile and non-volatile). The computer-readable storage media can store computer-executable instructions that implement at least a portion of the functional modules that comprise the base dose calculation tool 300 described herein. When the computer-executable instructions are executed by the processor, the system 200 is thus configured to perform the operations described herein, such as the operations of the method 100 described above.

[0060] The computing device 210 may further include various hardware devices (not shown) for implementing portions of the base dose calculation tool 300. For example, the computing device 210 may include a graphics device having a graphics processing unit (GPU), dedicated memory, and / or a hardware interface for coupling the graphics device to a display. Additionally, the computing device 210 may include physical hardware ports and / or wireless interfaces (e.g., Bluetooth, wireless USB, etc.) that can couple the computing device 210 to various devices of the system 200 (e.g., but not limited to, the treatment planning system 400).

[0061] According to one embodiment, the base dose calculation tool 300 determines a base dose to be exported to the treatment planning system 400 for planning radiation therapy. The base dose calculation tool 300 obtains feature information 212 indicative of various features of interest. For example, the feature information 212 may include contours of regions of interest such as OARs and target volumes. The base dose calculation tool 300 also receives optimization information such as treatment parameters and dose constraints 214, where the dose constraints indicate dose constraints for each feature indicated by the feature information 212. The base dose calculation tool 300 also obtains additional treatment information 216 and previous treatment information 218. In one embodiment, the additional treatment information 216 may include radiobiological parameters for a particular additional treatment. Parameters may be provided for each feature indicated by the feature information 212. The previous treatment information 218 may be a BED map of a previous treatment registered to a simulation image in some embodiments. The simulation image may be a DICOM series that is utilized by the treatment planning system 400 during treatment planning. Prior treatment information 218 is sometimes referred to herein as base treatment information. Base or prior treatment information 218 may include information related to prior or base treatments for a patient, as well as information related to lab notes and / or patient notes, which may include biological information related to a biological plan even if the base treatment was not administered.

[0062] Using these inputs, the base dose calculation tool 300 generates a base dose that is exported to the treatment planning system 400. The base dose may be generated using the base dose relationships derived from the BED model described above.

[0063] Referring to FIG. 7, a schematic block diagram of an exemplary and non-limiting embodiment of a base dose calculation system 500 is illustrated. As shown in FIG. 7, the system 500 includes a computing device 210, a base dose calculation tool 300, and a treatment planning system 400. In addition, in the embodiment of FIG. 7, a registration engine 510 is provided. According to one aspect, the registration engine 510 receives registration information 512 and registers corresponding voxels of various images together. The registration information 512 can include, for example, spatio-temporal registration information that precisely links points in space / time on various images together. The registration engine 510, in one aspect, provides a consistent basis for determining and manipulating BED amounts when the base dose calculation tool 300 determines base dose values.

[0064] Referring to FIG. 8, a schematic block diagram of another exemplary and non-limiting embodiment of a base dose calculation system 600 is illustrated. As shown in FIG. 7, the system 600 includes a computing device 210, a base dose calculation tool 300, and a treatment planning system 400. In addition, in the embodiment of FIG. 8, a recurrence treatment engine 610 is provided. As described above, the additional treatment may be for a cancer suspected of recurrence. Upon recurrence, future additional treatments may then be required. In this embodiment, the base treatment information 218 may include information regarding the location and time of expected recurrence. The base treatment information 218 is received by the modeling engine 614 to generate a prediction model or the time and location of the recurrence. The simulation engine 612 may use the prediction model to generate a simulated treatment to be delivered in the future, and may generate a predicted or future treatment dosimetry based on the simulated treatment. This prediction may be utilized by the base dose calculation tool 300 to determine a base dose value to be exported to the treatment planning system 400 for future planning of this recurrence treatment.

[0065] FIG. 9 is a schematic block diagram of an exemplary and non-limiting embodiment of a computing device 210 associated with the system 200 of FIG. 7. As shown in FIG. 8, the computing device 210 includes one or more processors 402 configured to execute computer-executable instructions, such as instructions configuring the base dose calculation tool 300, the registration engine 510, and the recurrence treatment engine 610. Such computer-executable instructions can be stored on one or more computer-readable media, including non-transitory computer-readable storage media, such as the storage 404. For example, the storage 404 can include non-volatile storage for persistently storing the base dose calculation tool 300, the registration engine 510, the recurrence treatment engine 610, and / or the data 410 (e.g., parameters, contours, BED maps, feature information, operation data, etc.). The storage 404 can also include volatile storage for storing the base dose calculation tool 300, the registration engine 510, the recurrence treatment engine 610, and other data 410 (or portions thereof) during execution by the processor 402.

[0066] The computing device 210 includes a communication interface 406 for coupling the computing device 210 to various remote systems (e.g., a treatment planning system, etc.). The communication interface 406 can be a wired or wireless interface. The communication interface 406 includes, for example, but is not limited to, a WiFi interface, an Ethernet interface, an optical fiber interface, a cellular radio interface, a satellite interface, etc. An I / O interface 408 is also provided for coupling the computing device 210 to various input / output devices, such as a display, a touch screen, a keyboard, a mouse, a touch pad, etc. By way of example, the I / O interface 408 can include, but is not limited to, a wired or wireless interface, such as a USB interface, a serial interface, a WiFi interface, a short-range RF interface (Bluetooth), an infrared interface, a near field communication (NFC) interface, etc.

[0067] The word "exemplary" is used herein to mean serving as an example, instance, or illustration. An aspect or design described herein as "exemplary" is not necessarily to be construed as advantageous over other aspects or designs. Rather, use of the word exemplary is intended to present a concept in a concrete manner. As used herein, the term "or" is intended to mean an inclusive "or" rather than an exclusive "or". That is, unless otherwise specified or clear from the context, "X employs A or B" is intended to mean any of the natural and inclusive permutations. That is, if X employs A, if X employs B, or if X employs both A and B, then "X employs A or B" is satisfied in any of the foregoing cases. Also, at least one of A and B, etc. generally means A or B, or both A and B. Moreover, the articles "a" and "an" as used in this application and the appended claims may be construed generally to mean "one or more" unless otherwise specified or clearly directed to the singular form from the context.

[0068] Although the subject matter has been described in language specific to structural features and / or methodological acts, it should be understood that the subject matter defined in the appended claims is not necessarily limited to the specific features or acts described above. Rather, the specific features and acts described above are disclosed as exemplary forms of implementing the claims. Of course, those skilled in the art will recognize that many modifications can be made to this configuration without departing from the scope or spirit of the claimed subject matter.

[0069] Also, while the present disclosure has been shown and described with respect to one or more embodiments, equivalent changes and modifications will occur to those skilled in the art based on reading and understanding this specification and the accompanying drawings. The present disclosure includes all such modifications and alterations and is limited only by the scope of the following claims. In particular, with respect to the various functions performed by the above-mentioned components (e.g., elements, resources, etc.), the terms used to describe such components are intended to correspond to any components that perform the specified function of the described components (e.g., functionally equivalent) even if they are not structurally equivalent to the disclosed structures that perform the functions in the exemplary embodiments illustrated herein of the present disclosure, unless otherwise indicated.

[0070] In addition, while a particular feature of the present disclosure may be disclosed with respect to only one of several embodiments, such feature may be combined with one or more other features of other embodiments as may be desirable and advantageous for any given or particular application.Furthermore, to the extent that the terms "including," "having," "has," "comprising," or variations thereof are used in either the detailed description or the claims, such terms are intended to be inclusive in a manner similar to the term "comprising."

[0071] Having described the above embodiments, it will be apparent to those skilled in the art that the above methods and apparatus may incorporate changes and modifications without departing from the general scope of the invention. The present disclosure is intended to include all such modifications and alterations insofar as they come within the scope of the appended claims or the equivalents thereof.

Claims

1. A processor coupled to a memory storing computer-executable instructions, the instructions, when executed by the processor, obtaining information about a patient's baseline treatment; obtaining additional treatment information relating to an additional treatment to be administered to the patient; determining a base dose distribution based on the base treatment information and the additional treatment information and according to a base dose relationship derived from a biologically effective dose (BED) model associated with the additional treatment; exporting the base dose distribution to a treatment planning system for planning the additional treatment; The system comprises the processor configured to execute the

2. The system of claim 1 , wherein the base therapy is a different therapy than the additional therapy.

3. The system of claim 1 , wherein the base therapy is a simulated therapy to be administered in the future.

4. The system of claim 3 , wherein the base treatment information includes a predictive model of timing and location of recurrence.

5. The system of claim 1 , wherein the base treatment information includes a BED map of the base treatment registered to a simulation image.

6. 2. The system of claim 1, wherein the additional treatment information includes feature information indicative of at least features of interest, optimization information indicative of dose optimization parameters for at least each feature indicated by the feature information, and user-defined parameters associated with the additional treatment for each feature indicated by the feature information.

7. The processor further comprises: matching the features contained in the feature information with respective user-defined and optimized parameters; Substituting the user-defined parameters and the optimized parameters as mapped to generate a BED map of the additional treatment; The system of claim 6 , configured to execute:

8. The system of claim 7 , wherein the processor is further configured to determine the base dose distribution based on the BED map of the additional treatment and information of the base treatment.

9. The system of claim 1 , wherein the base dose relationship converts a BED to a physical dose distribution suitable for the treatment planning system.

10. obtaining information about a patient's baseline treatment; obtaining additional treatment information relating to an additional treatment to be administered to the patient; determining a base dose distribution based on the base treatment information and the additional treatment information according to a base dose relationship derived from a biologically effective dose (BED) model associated with the additional treatment; exporting the base dose distribution to a treatment planning system for planning the additional treatment; The method includes:

11. The method of claim 10 , wherein the base therapy is a different therapy than the additional therapy.

12. The method of claim 10 , wherein the base therapy is a simulated therapy to be administered in the future.

13. The method of claim 12, wherein the base treatment information includes a predictive model of time and location of recurrence.

14. The method of claim 10 , wherein the base treatment information includes a BED map of the base treatment registered to a simulation image.

15. 11. The method of claim 10, wherein the additional treatment information includes feature information indicative of at least features of interest, optimization information indicative of constraints for at least each feature indicated by the feature information, and user-defined parameters associated with the additional treatment for each feature indicated by the feature information.

16. matching the features contained in the feature information with respective user-defined parameters and constraints; Substituting the user-defined parameters and the constraints as mapped to generate a BED map of the additional treatment; The method of claim 15 further comprising:

17. The method of claim 16, further comprising determining the base dose distribution based on the BED map of the additional treatment and information of the base treatment.

18. The method of claim 10 , wherein the base dose relationship converts a BED to a physical dose distribution suitable for the treatment planning system.

19. 1. A non-transitory computer readable storage medium having stored thereon computer executable instructions for a base dose calculation tool, the instructions, when executed, performing: obtaining base treatment information related to a base treatment of the patient; obtaining additional treatment information relating to an additional treatment to be administered to the patient; determining a base dose distribution based on the base treatment information and the additional treatment information and according to a base dose relationship derived from a biologically effective dose (BED) model associated with the additional treatment; exporting the base dose distribution to a treatment planning system for planning the additional treatment; 23. A non-transitory computer readable storage medium for configuring a processor to execute the method of claim 22.

20. 20. The non-transitory computer readable storage medium of claim 19, wherein the base therapy is a different therapy than the additional therapy.

21. 20. The non-transitory computer-readable storage medium of claim 19, wherein the base therapy is a simulated therapy to be administered in the future.

22. 22. The non-transitory computer readable storage medium of claim 21, wherein the base treatment information includes a predictive model of time and location of recurrence.

23. 20. The non-transitory computer readable storage medium of claim 19, wherein the base information includes a BED map of the base treatment registered to a simulation image.

24. 20. The non-transitory computer-readable storage medium of claim 19, wherein the additional treatment information includes at least feature information indicative of features of interest, optimization information indicative of optimization parameters for each feature indicated by the feature information, and user-defined parameters associated with the additional treatment for each feature indicated by the feature information.

25. The processor further comprises: matching the features contained in the feature information with respective user-defined and optimized parameters; Substituting the user-defined parameters and the optimized parameters as mapped to generate a BED map of the additional treatment; determining a base dose distribution based on the BED map of the additional treatment and the base information; 25. The non-transitory computer-readable storage medium of claim 24 configured to execute:

26. 26. The non-transitory computer readable storage medium of claim 25, wherein the base dose relationship converts a BED to a physical distribution suitable for the treatment planning system.

Citation Information

Patent Citations

  • Results-Based Radiation Therapy Treatment Plan

    JP2018522683A

  • Radiation therapy support device, radiation therapy system and radiation therapy support method

    JP2020127722A

  • Joint optimization of radionuclide and external beam radiotherapy

    US20210228907A1